Cite
HARVARD Citation
Alonso, S. et al. (2017). Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real‐life cohort. Journal of viral hepatitis. 24 (4), pp. 304-311. [Online].